Edgewise Therapeutics, Inc. (EWTX)
NASDAQ:EWTX
Want to see EWTX full AI Analyst Report?
EWTX Stock Chart & Stats
$34.43
-$0.39(-1.54%)
At close: 4:00 PM EST
$34.43
-$0.39(-1.54%)
Day’s Range― - ―
52-Week Range$12.15 - $40.77
Previous CloseN/A
Volume107.81K
Average Volume (3M)1.24M
Market Cap
$4.01B
Enterprise Value$3.65B
Total Cash (Recent Filing)$499.56M
Total Debt (Recent Filing)$3.79M
Price to Earnings (P/E)―
Beta2.11
Next Earnings
Aug 06, 2026EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.66
Shares Outstanding107,593,000
10 Day Avg. Volume997,768
30 Day Avg. Volume1,237,861
Financial Highlights & Ratios
PEG Ratio-1.23
Price to Book (P/B)4.89
Price to Sales (P/S)0.00
P/FCF Ratio-17.76
Enterprise Value/Market Cap0.91
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.18K
Enterprise Value/Ebitda-19.44
Forecast
1Y Price Target
$44.36Price Target Upside28.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.99
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet And Low LeverageVery low debt and sizable assets provide durable financial flexibility for a clinical-stage biotech. This cushion supports sustained R&D spending, reduces immediate refinancing pressure, and gives management optionality to fund trials, partner selectively, or pursue strategic transactions without urgent capital markets reliance.
Large Upfront Proceeds From Asset SaleThe $1.55B upfront materially strengthens the company’s funding base and reduces near-term financing risk. Durable impact: proceeds can fund pivotal development, extend runway into approval stages, and permit disciplined investment in higher‑value cardiology programs without immediate dilution.
Strategic Refocus To Cardiovascular PipelineConcentrating resources on cardiology creates clearer strategic priorities and potential scale advantages in indication-specific expertise. With planned Phase 2 readouts and targeted development, the firm can allocate capital and talent to de‑risk a smaller set of higher‑value assets over the next 2–6 months and beyond.
Bears Say
High And Worsening Operating Cash BurnSustained and growing negative operating cash flow is a durable risk driver: it consumes balance sheet resources and can force prioritization of programs or require milestone‑based financings. Even after the sale, persistent burn will determine how long proceeds last and whether further capital raises are needed.
Pre-revenue Status With Materially Widening LossesAbsence of product revenue means long-term value depends entirely on successful clinical and regulatory outcomes. Widening losses reflect increasing development spend and create structural pressure on returns; until commercialization, the business lacks durable internal cash generation to offset burn.
Concentration And Execution Risk After DivestitureRefocusing reduces diversification: the firm’s prospects hinge on a few cardiology programs. Trial setbacks, regulatory delays, or clinical readout disappointments in one or two assets would disproportionately impair value and funding plans, increasing execution risk over the medium term.
Edgewise Therapeutics News
EWTX FAQ
What was Edgewise Therapeutics, Inc.’s price range in the past 12 months?
Edgewise Therapeutics, Inc. lowest stock price was $12.15 and its highest was $40.77 in the past 12 months.
What is Edgewise Therapeutics, Inc.’s market cap?
Edgewise Therapeutics, Inc.’s market cap is $4.01B.
When is Edgewise Therapeutics, Inc.’s upcoming earnings report date?
Edgewise Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 64 days.
How were Edgewise Therapeutics, Inc.’s earnings last quarter?
Edgewise Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$0.46 earnings per share for the quarter, beating the consensus estimate of -$0.485 by $0.025.
Is Edgewise Therapeutics, Inc. overvalued?
According to Wall Street analysts Edgewise Therapeutics, Inc.’s price is currently Undervalued.
Does Edgewise Therapeutics, Inc. pay dividends?
Edgewise Therapeutics, Inc. does not currently pay dividends.
What is Edgewise Therapeutics, Inc.’s EPS estimate?
Edgewise Therapeutics, Inc.’s EPS estimate is -0.48.
How many shares outstanding does Edgewise Therapeutics, Inc. have?
Edgewise Therapeutics, Inc. has 107,593,000 shares outstanding.
What happened to Edgewise Therapeutics, Inc.’s price movement after its last earnings report?
Edgewise Therapeutics, Inc. reported an EPS of -$0.46 in its last earnings report, beating expectations of -$0.485. Following the earnings report the stock price went down -3.812%.
Which hedge fund is a major shareholder of Edgewise Therapeutics, Inc.?
Currently, no hedge funds are holding shares in EWTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Edgewise Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.36 (28.84% Upside)
$44.36 (28.84% Upside)
Blogger Sentiment
Bullish
EWTX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 522.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $208.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.2%
Last 30 Days ▲ 4.7%
Last 30 Days ▲ 4.7%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
153.57%
12-Months-Change
Fundamentals
Return on Equity
-32.55%
Trailing 12-Months
Asset Growth
14.11%
Trailing 12-Months
Company Description
Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
EWTX Stock 12 Month Forecast
Average Price Target
$44.36
▲(28.84% Upside)
Technical Analysis
Viridian Therapeutics
―
Pharvaris
―
Vera Therapeutics
―
Janux Therapeutics Inc
―
Biohaven Ltd.
―
Ownership Overview
0.95% Insiders
12.71% Mutual Funds
72.96% Other Institutional Investors
4.38% Public Companies and
Individual Investors